Skip to main content Back to Top
Advertisement

11/21/2022

Lidocaine with Epinephrine Injection

Products Affected - Description

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 20 mL vial, 100 count, NDC 00409-3178-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 30 mL vial, 100 count, NDC 00409-3178-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 50 mL vial, 100 count, NDC 00409-3178-03
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 20 mL vial, 100 count, NDC 00409-3182-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 30 mL vial, 100 count, NDC 00409-3182-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 50 mL vial, 100 count, NDC 00409-3182-03
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 100 count, NDC 00409-3177-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 30 mL vial, 25 count, NDC 00409-3181-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 5 mL glass ampule, 10 count, NDC 00409-1209-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-3183-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0481-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0482-17
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0482-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0482-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0483-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0483-57
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0487-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, sterile-pack 5 count, NDC 63323-0487-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0487-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 10 mL vial, 25 count, NDC 63323-0488-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, 25 count, NDC 63323-0488-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0489-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0489-27

Reason for the Shortage

    • Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
    • Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Fresenius Kabi has 0.5% Xylocaine with epinephrine (1:200,000) 50 mL vials on back order and the company estimates a release date of late-November to early-December 2022. The 1% Xylocaine with epinephrine (1:200,000) 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of late-November to early-December 2022 for the 10 mL vials, late-November 2022 for the 20 mL vials, and early-January 2023 for the 50 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials vials are on back order and the company cannot estimate a release date. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates a release date of mid-December 2022. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials vials in sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine with epinephrine (1:200,000) 10 mL and 30 mL vials are on back order and the company estimates a release date of late-November to early-December 2022 for the 10 mL vials and early-December 2022 for the 30 mL vials. The 2% Xylocaine with epinephrine (1:200,000) 20 mL and 50 mL vials are on back order and the company estimates a release date of late-November 2022 for the 20 mL vials and mid- to late-December 2022 for the 50 mL vials. The 2% Xylocaine-MPF (1:200,000) 10 mL and 20 mL vials are on back order and the company estimates a release date of early-December 2022 for the 10 mL vials and mid-December 2022 for the 20 mL vials. Check wholesalers for inventory.
    • Pfizer has 0.5% lidocaine (1:200,000) 50 mL vials on back order and the company estimates a release date of November 2022. The 1% lidocaine (1:100,000) 20 mL, 30 mL, and 50 mL vials are on back order and the company estimates a release date of December 2022 for the 20 mL vials, November 2022 for the 30 mL vials, and January 2023 for the 50 mL vials. The 1.5% lidocaine (1:200,000) 5 mL glass ampules and 30 mL vials are on back order and the company estimates a release date of June 2023 for the 5 mL ampules and August 2023 for the 30 mL vials. The 2% lidocaine (1:200,000) 20 mL vials are on back order and the company estimates a release date of January 2023. The 2% lidocaine (1:100,000) 20 mL, 30 mL ,and 50 mL vials are on back order and the company estimates a release date of November 2022 for the 20 mL vials, January 2023 for the 30 mL vials, and December 2022 for the 50 mL vials.

Updated

Updated November 21, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.